Advertisement
Advertisement
UTHR
United Therapeutics Corp
566.99
USDSponsored
-1.59
-0.28%
May 18, 16:00 UTC -4
Closed
After-Market
566.76
-0.23
-0.04%
UTHR Earnings Reports
Positive Surprise Ratio
UTHR beat 21 of 42 last estimates.
50%
Next Report
Date of Next Report
Jul 28, 2026
Estimate for Q2 26 (Revenue/ EPS)
$825.30M
/$7.25
Implied change from Q1 26 (Revenue/ EPS)
+5.60%
/+24.57%
Implied change from Q2 25 (Revenue/ EPS)
+3.34%
/+13.10%
United Therapeutics Corp earnings per share and revenue
On May 06, 2026, UTHR reported earnings of 5.82 USD per share (EPS) for Q1 26, missing the estimate of 7.00 USD, resulting in a -16.92% surprise. Revenue reached 781.50 million, compared to an expected 812.86 million, with a -3.86% difference. The market reacted with a +4.29% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 8 analysts forecast an EPS of 7.25 USD, with revenue projected to reach 825.30 million USD, implying an increase of 24.57% EPS, and increase of 5.60% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
ARS Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.53
Actual
-$0.61
Surprise
-13.81%
ProKidney Corp. Class A Ordinary Shares
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.14
Actual
-$0.14
Surprise
+0.57%
Galectin Therapeutics Inc.
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.06
Actual
-$0.08
Surprise
-30.72%
NRX Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
$0.29
Actual
-$0.04
Surprise
-113.64%
Incannex Healthcare Limited - ADR
Report Date
May 15, 2026 For Q3 26
Estimate
-$0.94
Actual
-$11.22
Surprise
-1088.38%
Marker Therapeutics, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.16
Surprise
+14.44%
PLUS THERAPEUTICS, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.89
Actual
-$1.05
Surprise
-16.98%
VYNE Therapeutics Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.08
Surprise
+56.43%
Scienture Holdings, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.22
Actual
-$0.08
Surprise
+64.35%
60 Degrees Pharmaceuticals, Inc. Common Stock
Report Date
May 15, 2026 For Q1 26
Estimate
-$0.77
Actual
-$1.28
Surprise
-65.12%
FAQ
What were United Therapeutics Corp's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, United Therapeutics Corp reported EPS of $5.82, missing estimates by -16.92%, and revenue of $781.50M, -3.86% below expectations.
How did the market react to United Therapeutics Corp's Q1 2026 earnings?
The stock price moved up 4.29%, changed from $572.20 before the earnings release to $596.76 the day after.
When is United Therapeutics Corp expected to report next?
The next earning report is scheduled for Jul 28, 2026.
What are the forecasts for United Therapeutics Corp's next earnings report?
Based on 8
analysts, United Therapeutics Corp is expected to report EPS of $7.25 and revenue of $825.30M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement